New hope for Drug-Resistant leukemia: phase 3 trial launches
Disease control
Not yet recruiting
This study tests a new drug, TGRX-678, in adults with chronic-phase chronic myeloid leukemia (CML) whose cancer has stopped responding to or caused side effects from at least three prior treatments. Participants will receive either TGRX-678 or another standard drug chosen by thei…
Phase: PHASE3 • Sponsor: Shenzhen TargetRx Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC